| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8399469 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759351 | OTSUKA | Methods for administering aripiprazole |
Aug, 2023
(8 months ago) | |
| US8338428 | OTSUKA | Methods for administering aripiprazole |
Aug, 2023
(8 months ago) | |
| US8338427 | OTSUKA | Methods for administering aripiprazole |
Mar, 2025
(10 months from now) | |
| US11638757 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
| US11097007 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
| US10517951 | OTSUKA | Injectable preparation |
Apr, 2033
(8 years from now) | |
Abilify Asimtufii is owned by Otsuka.
Abilify Asimtufii contains Aripiprazole.
Abilify Asimtufii has a total of 7 drug patents out of which 2 drug patents have expired.
Expired drug patents of Abilify Asimtufii are:
- US8759351
- US8338428
Abilify Asimtufii was authorised for market use on 27 April, 2023.
Abilify Asimtufii is available in suspension, extended release;intramuscular dosage forms.
Abilify Asimtufii can be used as maintenance monotherapy treatment of bipolar i disorder, use of aripiprazole in extended release injectable suspension, treatment of schizophrenia.
The generics of Abilify Asimtufii are possible to be released after 23 April, 2033.
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 27 April, 2023
Treatment: Use of aripiprazole in extended release injectable suspension; Treatment of schizophrenia; Maintenance monotherapy treatment of bipolar i disorder
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ABILIFY ASIMTUFII family patents
